Skip to main content
. 2016 Feb 26;310(9):H1107–H1117. doi: 10.1152/ajpheart.00961.2015

Fig. 2.

Fig. 2.

Protein kinase G1α (PKG1α), phosphorylated-VASP, and cGMP levels in bovine pulmonary arteries untreated and treated with G6PD inhibitors. A and B: expression of PKG1α measured as dimer-to-monomer ratios and phosphorylated-VASP increased by inhibiting G6PD with DHEA (100 μM) or 6-AN (1 mM). C: cGMP levels in the samples are not changed. n = 5 in each group. *P < 0.05 vs. control; #P < 0.05 vs. treatments.